Breaking News Instant updates and real-time market news.

MS

Morgan Stanley

$51.27

-0.32 (-0.62%)

, WFC

Wells Fargo

$54.70

-0.48 (-0.87%)

13:38
06/14/18
06/14
13:38
06/14/18
13:38

Financials take a hit after Fed action further flattens yield curve

Shares of the financial sector ETF (XLF) and components like Citigroup (C) and Goldman Sachs (GS) are lower after The Federal Reserve raised its key short-term rate on Wednesday and signaled that two additional increases were on the way in 2018. RATE HIKE: On Wednesday afternoon, the Fed lifted the federal funds rate to a range of 1.75% to 2% and signaled that further rate hikes are on the way. The Fed now anticipates four rate hikes this year, higher than the three it had previously forecast. HIGHER CREDIT COSTS: The move will likely result in higher borrowing rates for consumers and businesses in the future. Yesterday's announcement resulted in a further flattening of the yield curve to its lowest level in more than 10 years. The shape of the yield curve is determined by the relationship between the short-and long-term interest rates of fixed-income securities issued by the U.S government. Banks typically make their money by borrowing at short-term rates and lending at longer-term rates. PRICE ACTION: Publicly traded companies in the space including Citi, Goldman Sachs, Bank of America (BAC), PMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC) are all lower in afternoon trading.

MS

Morgan Stanley

$51.27

-0.32 (-0.62%)

WFC

Wells Fargo

$54.70

-0.48 (-0.87%)

USB

U.S. Bancorp

$50.88

-0.21 (-0.41%)

C

Citi

$66.24

-1.09 (-1.62%)

BAC

Bank of America

$29.49

-0.355 (-1.19%)

GS

Goldman Sachs

$233.80

-0.12 (-0.05%)

JPM

JPMorgan

$108.14

-1.87 (-1.70%)

XLF

Financial Select Sector

$27.58

-0.26 (-0.93%)

  • 14

    Jun

  • 14

    Jun

  • 19

    Jun

  • 19

    Jun

  • 21

    Jun

  • 22

    Jun

  • 13

    Jul

  • 13

    Jul

  • 18

    Jul

  • 12

    Oct

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

  • 15

    Oct

MS Morgan Stanley
$51.27

-0.32 (-0.62%)

04/06/18
WELS
04/06/18
NO CHANGE
Target $330
WELS
Outperform
Goldman Sachs to benefit from market volatility, says Wells Fargo
Wells Fargo analyst Mike Mayo says rising volatility could push his above consensus estimates for Goldman Sachs (GS) even higher. Goldman could be one of the biggest volatility beneficiaries, Mayo tells investors in a research note. He notes Goldman generates the highest contribution from trading among the large U.S. banks, with Morgan Stanley (MS) being second. The analyst keeps an Outperform rating on Goldman shares with a $330 price target.
04/09/18
BERN
04/09/18
INITIATION
Target $51
BERN
Underperform
Morgan Stanley initiated with an Underperform at Bernstein
Bernstein initiated Morgan Stanley with an Underperform and $51 price target.
04/19/18
BMOC
04/19/18
NO CHANGE
Target $72
BMOC
Outperform
Morgan Stanley 'richly deserves' higher valuation multiple, says BMO Capital
BMO Capital analyst James Fotheringham kept his Outperform rating and $72 price target on Morgan Stanley after its Q1 earnings beat while also raising his FY18 EPS view to $4.78 from $4.51. The analyst cites his expectations of higher trading revenues and also points to lower EPS volatility relative to that Goldman Sachs (GS), even though Morgan Stanley's multiple of 9.7-times two-year-forward PE is below Goldman's 10-times.
04/18/18
BMOC
04/18/18
NO CHANGE
Target $245
BMOC
Market Perform
Goldman Sachs price target raised to $245 from $221 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Goldman Sachs (GS) to $245 after the company's Q1 revenue beat, saying it is "back to stealing market share in its core business" as its FICC - fixed income, currencies, and commodities - trading rose 23% vs. a 4% decline for peers. The analyst adds that while Goldman Sachs will continue to experience positive operating leverage, its valuation relative to Morgan Stanley (MS) cannot be justified, favoring the latter based on its greater exposure to higher-multiple asset management businesses. Fotheringham keeps his Market Perform rating on Goldman Sachs.
WFC Wells Fargo
$54.70

-0.48 (-0.87%)

04/17/18
BMOC
04/17/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America is the best of the 'big four' U.S. banks, says BMO Capital
BMO Capital analyst James Fotheringham kept his Market Perform rating and $34 price target on Bank of America (BAC) after its in-line Q1 earnings but raised his FY18 EPS view to $2.62 from $2.59 and FY19 view to $3.18 from $3.12. Fotheringham says than in contrast, he lowered earnings forecasts for JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) because of higher costs and lower revenues, but Bank of America's better than expected net interest income rise justifies his view of the bank as the "best of the bunch". The analyst also notes the bank's more favorable valuation trading at a below-average two-year-forward P/E multiple despite his forecast of double the core earnings growth rate of Bank of America's peers.
04/16/18
NOMU
04/16/18
NO CHANGE
Target $68
NOMU
Buy
Wells Fargo earnings underwhelming, but not a value trap, says Nomura
Nomura Instinet analyst Bill Carcache lowered his price target for Wells Fargo to $68 from $72 saying Friday's earnings results were "underwhelming" as the company reported softer revenue growth. The analyst, however, continues to believe that shares of Wells Fargo are "not a value trap." Shareholders "able to weather the current storm" will be rewarded with 10% earnings growth, mid- to high-teens return on tangible equity, and a multiple rerating when the market regains confidence, Carcache tells investors in a research note. He keeps a Buy rating on the shares.
04/30/18
04/30/18
UPGRADE

Outperform
Wells Fargo double upgraded to Outperform at Macquarie
Macquarie analyst David Konrad upgraded Wells Fargo to Outperform from Underperform with a $61 price target citing attractive valuation, low expectations, and near-term catalysts. Konrad said valuation and consensus estimates have finally come down and said shares are trading at 11.3x his 2019 "stressed earnings" estimate, compared to super regionals trading at 12.3x. The analyst expects low expense guidance at the upcoming investor day and passing CCAR in June to serve as positive catalysts for shares.
04/16/18
BARD
04/16/18
NO CHANGE
Target $62
BARD
Outperform
Lower expectations limit Wells Fargo downside, says Baird
Baird analyst David George said Wells Fargo reported messy Q1 results, but lowered expectations should limit the downside in the shares. The analyst said core fees were weak, but expenses were in line as was loan growth. George maintained his Outperform rating and $62 price target on Wells Fargo shares.
USB U.S. Bancorp
$50.88

-0.21 (-0.41%)

04/04/18
DBAB
04/04/18
UPGRADE
Target $50
DBAB
Buy
Citizens Financial upgraded to Buy with $50 target at Deutsche Bank
Deutsche Bank analyst Matthew O'Connor last night upgraded Citizens Financial Group (CFG) to Buy with an unchanged price target of $50. The analyst upgrades the stock following the recent pullback ahead of the Q1 earnings season. U.S. Bancorp (USB) remains his top pick among U.S. Banks.
05/11/18
SBSH
05/11/18
UPGRADE
Target $58
SBSH
Buy
Citi upgrades U.S. Bancorp, says opportune time to build positions
Citi analyst Keith Horowitz upgraded U.S. Bancorp to Buy from Neutral with an unchanged price target of $58. Now is an opportune time to build positions in the stock after three years of significant underperformance, Horowitz tells investors in a research note. He believes the drivers of the underperformance have largely played out and that U.S. Bancorp's efficiency ratio will improve from here. Further, the bank's "strong" credit quality profile can be a differentiator as the cycle gets into the latter innings, Horowitz contends. He says U.S. Bancorp is one of the best ways for investors looking to add exposure to the banks.
05/11/18
05/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Overweight from Neutral at JPMorgan with analyst Philip Cusick saying after a meeting with CEO Lowell McAdam, he has a better understanding that Verizon's "organic approach to wireless has the company on an increasingly stable footing." 2. Mosaic (MOS) upgraded to Outperform from Sector Perform at RBC Capital with analyst Andrew Wong saying that it is "hard to ignore the improving undercurrents in both phosphate and potash markets." 3. Ultragenyx (RARE) upgraded to Overweight from Equal Weight at Barclays with analyst Gena Wang saying she thinks a higher price target for Crysvita could drive upside to revenue growth expectations. 4. U.S. Bancorp (USB) upgraded to Buy from Neutral at Citi with analyst Keith Horowitz saying now is an opportune time to build positions in the stock after three years of significant underperformance. 5. AMC Networks (AMCX) upgraded to Buy from Hold at Gabelli with the firm saying it remains an excelling company with opportunities to leverage its recent programming momentum into increased advertising and affiliate fees. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/11/18
SBSH
05/11/18
UPGRADE
SBSH
Buy
U.S. Bancorp upgraded to Buy from Neutral at Citi
Citi analyst Keith Horowitz upgraded U.S. Bancorp to Buy with a $58 price target.
C Citi
$66.24

-1.09 (-1.62%)

04/11/18
04/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at HSBC with analyst Alevizos Alevizakos saying he sees improved profitability in the near-term, driven by U.S. dollar depreciation and tax reform, re-rating the shares higher. 2. BHP Billiton (BHP) upgraded to Buy from Hold at Deutsche Bank with analyst Liam Fitzpatrick saying the shares offer compelling value at current levels. 3. Mattel (MAT) upgraded to Hold from Underperform at Jefferies with analyst Stephanie Wissink saying the company's near-term risks are largely known and priced into the shares. 4. AeroVironment (AVAV) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he sees the company benefiting from tailwinds including an improving defense budget environment, a heightened global threat environment, and "as strong a pipeline of opportunities" as he has seen in ten years. 5. Helmerich & Payne (HP) upgraded to Market Perform from Underperform at Wells Fargo with analyst Judson Bailey citing strength in the land rig market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/18
HSBC
04/11/18
UPGRADE
Target $85
HSBC
Buy
Citi upgraded to Buy from Hold at HSBC
HSBC analyst Alevizos Alevizakos upgraded Citi to Buy and raised his price target for the shares to $85 from $82. The analyst sees improved profitability in the near-term, driven by U.S. dollar depreciation and tax reform, re-rating the shares higher. He believes the market is not fully appreciating Citi's leading credit card franchise and its growth prospects in Mexico.
05/17/18
DAIW
05/17/18
DOWNGRADE
DAIW
Buy
Citi downgraded to Buy from Strong Buy at Daiwa
BAC Bank of America
$29.49

-0.355 (-1.19%)

04/03/18
BMOC
04/03/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America pullback provides a buying opportunity, says BMO Capital
BMO Capital analyst James Fotheringham says that the recent near-10% pullback in the Bank of America stock price provides investors with a buying opportunity. The analyst contends that the bank's stock trades much more closely in line with short term interest rates rather than the 10-year and believes that its net interest margins will prove to be "insensitive" to lower yields on the benchmark as well as higher LIBOR-OIS spreads. Fotheringham keeps his $34 price target and Market Perform rating on Bank of America, adding that its current two-year-forward P/E valuation multiple is close to its long-term historical average.
02/02/18
MSCO
02/02/18
NO CHANGE
MSCO
BofA, JPMorgan, Citi best positioned for tougher CCAR test, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck said she had expected an easier stress test from the Federal Reserve but that the 2018 CCAR test actually seems tougher than last year, given the more intense recessions and lower asset prices modeled in it. A tougher test makes her less optimistic on her strong payout growth expectations, said Graseck, who sees Bank of America (BAC), JPMorgan (JPM) and Citi (C) as best positioned to "weather the storm" and increase payouts given their resilient balance sheets and significant excess capital. She sees Goldman Sachs (GS), which recently cut buybacks, as at risk from a tougher test, which likely weighs on the bank's 2018 ask, Graseck added.
01/31/18
DBAB
01/31/18
NO CHANGE
Target $15
DBAB
Sell
GE likely to be dropped from Dow 30 index, says Deutsche Bank
General Electric (GE) is likely to be dropped from the Dow Jones Industrial Average after being in the index of 30 companies for over 110 years as an original member since 1896, Deutsche Bank analyst John Inch tells investors in a research note. The chances that GE could be removed from the Dow are increasing as the company continues to face "substantial challenges," the analyst writes. These include "earnings and cash pressure, tough global power generation markets, aggressive downsizing, shrinking its portfolio, management shake-up and SEC investigations," Inch argues. He sees "headline risk" as the most significant risk factor if GE were to be dropped from the Dow, "potentially amplified by GE's high mix of retail investors." Inch notes that the last major Dow shakeup occurred in September 2003, when American Airlines (AAL), Bank of America (BAC) and Hewlett Packard (HPQ) were removed and Goldman Sachs (GS), Nike (NKE) and Verizon (VZ) were added. Inch has a Sell rating on General Electric with a $15 price target. The shares closed yesterday down 33c to $15.95.
GS Goldman Sachs
$233.80

-0.12 (-0.05%)

04/18/18
OPCO
04/18/18
NO CHANGE
Target $308
OPCO
Outperform
Goldman Sachs price target raised to $308 from $280 at Oppenheimer
Oppenheimer analyst Chris Kotowski raised his price target for Goldman Sachs to $308 from $280 after the company posted a "strong" rebound from last year's dismal quarter and posted a significant upside surprise. The analyst reiterates an Outperform rating on the shares.
04/18/18
ARGS
04/18/18
NO CHANGE
ARGS
Hold
Goldman Sachs earnings inherently 'volatile', says Argus
Argus analyst Stephen Biggar keeps his Hold rating on Goldman Sachs after its Q1 earnings beat, saying the company's as "strength in underwriting, equities trading and securities lending offset weaker financial advisory revenue". Biggar further notes that as a "capital markets pure play", Goldman Sachs has move volatile earnings than other large global banks and is more dependent on client activity. The analyst further cites Q1 outperformance as a result of a "ripe environment" for Goldman's business mix, but does not expect market volatility to continue.
04/18/18
FBCO
04/18/18
NO CHANGE
Target $280
FBCO
Neutral
Goldman Sachs price target raised to $280 from $274 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke raised her price target for Goldman Sachs to $280 from $274 following quarterly results. The analyst reiterates a Neutral rating on the shares.
JPM JPMorgan
$108.14

-1.87 (-1.70%)

06/08/18
BERN
06/08/18
NO CHANGE
BERN
Bernstein offers list of possible CEOs for Amazon-Berkshire-JPMorgan venture
After Berkshire' (BRK.A) Warren Buffett and JPMorgan's (JPM) Jamie Dimon announced on CNBC that they have selected a CEO for their healthcare joint venture with Amazon (AMZN) and added that they would announce the name in about two weeks, Bernstein analyst Lance Wilkes noted that Geisinger CEO David Feinberg denied accepting the position and said he is committed to Geisinger. The ultimate choice of the CEO will inform on the intended scope of the NewCo and how the companies will prioritize strategic direction and needed capabilities, said Wilkes, who offered a list of potential CEO candidates that includes Gary Loveman, Rick Jelinek, Matt Manders, Patrick Conway, Amir Rubin, Owen Tripp, Chris Grant, Marc Harrison, Andy Slavitt, Todd Park and Peter Orszag.
04/11/18
HSBC
04/11/18
INITIATION
Target $111
HSBC
Hold
JPMorgan initiated with a Hold at HSBC
HSBC analyst Alevizos Alevizakos started JPMorgan with a Hold rating and $111 price target. The analyst sees minimal share upside from current valuation levels.
04/11/18
04/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL), Apple (AAPL), and Facebook (FB) were initiated with a Buy at Monness Crespi. 2. Caterpillar (CAT) initiated with a Buy at Buckingham. 3. JPMorgan (JPM) initiated with a Hold at HSBC. 4. eBay (EBAY) assumed with an Overweight at KeyBanc. 5. Ericsson (ERIC) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
XLF Financial Select Sector
$27.58

-0.26 (-0.93%)

TODAY'S FREE FLY STORIES

SEAS

SeaWorld

$29.91

-0.19 (-0.63%)

15:35
09/24/18
09/24
15:35
09/24/18
15:35
Options
SeaWorld put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$95.05

-0.8 (-0.83%)

, IBM

IBM

$149.98

-1.31 (-0.87%)

15:31
09/24/18
09/24
15:31
09/24/18
15:31
Periodicals
Walmart requires lettuce, spinach suppliers to join blockchain, WSJ reports »

In a letter to suppliers,…

WMT

Walmart

$95.05

-0.8 (-0.83%)

IBM

IBM

$149.98

-1.31 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 22

    Oct

  • 28

    Oct

  • 15

    Nov

  • 03

    Mar

FL

Foot Locker

$47.57

-0.71 (-1.47%)

15:25
09/24/18
09/24
15:25
09/24/18
15:25
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

CDNA

CareDx

$26.73

0.75 (2.89%)

, NTRA

Natera

$23.95

-0.23 (-0.95%)

15:25
09/24/18
09/24
15:25
09/24/18
15:25
Conference/Events
Piper Jaffray biotech analysts to hold an analyst/industry conference call »

Biotech Analysts discuss…

CDNA

CareDx

$26.73

0.75 (2.89%)

NTRA

Natera

$23.95

-0.23 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 01

    Oct

  • 15

    Nov

  • 27

    Nov

SBUX

Starbucks

$56.91

-0.49 (-0.85%)

15:24
09/24/18
09/24
15:24
09/24/18
15:24
Periodicals
Starbucks plans 'significant changes' to company structure, Bloomberg says »

Starbucks is planning an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TMK

Torchmark

$88.45

-0.51 (-0.57%)

15:17
09/24/18
09/24
15:17
09/24/18
15:17
Syndicate
Breaking Syndicate news story on Torchmark »

Torchmark files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/24/18
09/24
15:17
09/24/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/24/18
09/24
15:16
09/24/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$95.09

-0.76 (-0.79%)

15:10
09/24/18
09/24
15:10
09/24/18
15:10
Periodicals
Walmart requires lettuce, spinach suppliers to join blockchain, WSJ reports »

In a letter to suppliers,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 15

    Nov

  • 03

    Mar

WFC

Wells Fargo

$54.35

-0.6 (-1.09%)

15:10
09/24/18
09/24
15:10
09/24/18
15:10
Options
Wells Fargo with a notable option spread as shares slip »

Wells Fargo with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

BSX

Boston Scientific

$38.37

0.61 (1.62%)

15:05
09/24/18
09/24
15:05
09/24/18
15:05
Options
Boston Scientific call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

SWCH

Switch

$10.83

-0.23 (-2.08%)

, INTC

Intel

$46.92

0.28 (0.60%)

15:04
09/24/18
09/24
15:04
09/24/18
15:04
Hot Stocks
Intel Capital sells about 1.728M shares of Switch »

According to a regulatory…

SWCH

Switch

$10.83

-0.23 (-2.08%)

INTC

Intel

$46.92

0.28 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 22

    Oct

MTNB

Matinas BioPharma

$0.55

0.1392 (33.98%)

, AMRN

Amarin

$11.62

8.62 (287.33%)

15:03
09/24/18
09/24
15:03
09/24/18
15:03
Recommendations
Matinas BioPharma, Amarin analyst commentary  »

Amarin's Vascepa…

MTNB

Matinas BioPharma

$0.55

0.1392 (33.98%)

AMRN

Amarin

$11.62

8.62 (287.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

15:00
09/24/18
09/24
15:00
09/24/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

KOS

Kosmos

$9.45

-0.06 (-0.63%)

14:58
09/24/18
09/24
14:58
09/24/18
14:58
Hot Stocks
Breaking Hot Stocks news story on Kosmos »

First Reserve GP XIII…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$10.76

-0.3 (-2.71%)

14:58
09/24/18
09/24
14:58
09/24/18
14:58
Conference/Events
Switch management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

CGC

Canopy Growth

$52.68

2.92 (5.87%)

, CVSI

CV Sciences

$0.00

(0.00%)

14:55
09/24/18
09/24
14:55
09/24/18
14:55
Hot Stocks
NY Governor signs bill adding pain management as condition for medical marijuana »

New York Governor Andrew…

CGC

Canopy Growth

$52.68

2.92 (5.87%)

CVSI

CV Sciences

$0.00

(0.00%)

ACBFF

Aurora Cannabis

$0.00

(0.00%)

CRON

Cronos Group

$11.80

-0.71 (-5.68%)

TLRY

Tilray

$105.00

-18.155 (-14.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Oct

SBUX

Starbucks

$56.88

-0.52 (-0.91%)

14:50
09/24/18
09/24
14:50
09/24/18
14:50
Periodicals
Starbucks plans 'significant changes' to company structure, Bloomberg says »

Starbucks'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

RRGB

Red Robin

$38.65

-0.55 (-1.40%)

14:50
09/24/18
09/24
14:50
09/24/18
14:50
Conference/Events
Red Robin management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ASNA

Ascena Retail

$3.94

-0.29 (-6.86%)

14:49
09/24/18
09/24
14:49
09/24/18
14:49
Options
Ascena Retail options imply 24.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AMRN

Amarin

$11.13

8.13 (271.00%)

, SNY

Sanofi

$43.33

-0.28 (-0.64%)

14:48
09/24/18
09/24
14:48
09/24/18
14:48
Hot Stocks
Amarin CEO says Vascepa 'more analogous' to statins than PCSK9 inhibitors »

Amarin CEO John Thero…

AMRN

Amarin

$11.13

8.13 (271.00%)

SNY

Sanofi

$43.33

-0.28 (-0.64%)

REGN

Regeneron

$388.88

-1.67 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

TRXC

TransEnterix

$6.70

0.27 (4.20%)

14:45
09/24/18
09/24
14:45
09/24/18
14:45
Options
TransEnterix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 02

    Oct

  • 27

    Nov

SPPI

Spectrum

$17.18

-4.19 (-19.61%)

14:44
09/24/18
09/24
14:44
09/24/18
14:44
Hot Stocks
Spectrum drops over 20% after releasing poziotinib data from Phase 2 study »

Shares of Spectrum are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

JNJ

Johnson & Johnson

$140.67

-2.18 (-1.53%)

14:43
09/24/18
09/24
14:43
09/24/18
14:43
Periodicals
J&J talc cancer case in California ends in mistrial, Bloomberg reports »

Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

VSTM

Verastem

$8.98

0.31 (3.58%)

14:39
09/24/18
09/24
14:39
09/24/18
14:39
Hot Stocks
Verastem's Duvelisib approved by FDA »

Duvelisib capsules for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 05

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.